ALK-positive NSCLC: Current landscape
ALK-positive NSCLC: Current landscape
How the WIN consortium achieves its goals
The translational element of the WIN consortium
Making oncology global with the WIN consortium
An overview of the WIN consortium
The WIN symposium 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC
Entrectinib in NTRK fusion-positive non-small cell lung cancer
Using CT imaging to find radiomic signatures in surgically resected NSCLC
The role of afatinib in patients with EGFR NSCLC
ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model